Abstract
The article analyzes data from clinical studies on the efficacy and safety of azilsartan medoxomil/chlorthalidone combination and its components. According to the analyzed sources, both individual components and their combination have proven their efficacy and safety in patients with hypertension, including those with comorbid pathology. Azilsartan medoxomil demonstrated greater efficacy with comparable safety in terms of lowering blood pressure, both office and ambulatory, compared to candesartan, valsartan, olmesartan. Chlorthalidone showed greater hypotensive efficacy compared to hydrochlorothiazide and proved its protective effect in cardiovascular risk reduction. The combination of azilsartan medoxomil/chlorthalidone, in turn, has proven its safety and greater hypotensive efficacy compared to both the combination of olmesartan medoxomil/hydrochlorothiazide and azilsartan medoxomil/hydrochlorothiazide.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call